Parkway Medical Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00997087
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

buprenorphine (1 trial)

Drugs in Phase 2 Trials (1)

flumazenil (mazicon ) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Compulsive Personality Disorder (Phase 2)

Obsessive-Compulsive Disorder (Phase 2)

Opioid-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2